Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025EBioMedicineOpen Access

Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL

View Full Paper
Ask AI
Bookmark
Share

Authors

BGBerta González‐MartínezVGVíctor Galán‐GómezANAlfonso Navarro‐Zapata

Discussion

Loading...

Member takes

Overview

Observational analysis demonstrates promising complete remission rates in pediatric patients with B-ALL, indicating multifaceted approaches are crucial.

Key Points

  • Complete remission was achieved in 8 out of 10 patients with high-risk B-ALL treated with tandem CAR T-cells.
  • At the 18-month follow-up, the overall survival rate was 70%, suggesting effective long-term outcomes for this therapy.
  • Increased high-grade CRS and inflammatory markers correlated with high tumor burden prior to treatment.
  • This approach requiring optimized management strategies and bridging therapies continues to present significant challenges.

Cite This Study

González‐Martínez et al. (2025) studied this question.

synapsesocial.com/papers/68c24126b210217d6479e3d0https://doi.org/10.1016/j.ebiom.2025.105872
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results2025
  2. 2Human CART22.19 Therapy in Refractory Pediatric B-ALL: Insights from a Named-Patient Cohort2025
  3. 3CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial2025 · 2 citations
  4. 4Safety and efficacy of CD19-targeted CAR-T-cell therapy for patients with relapsed or refractory TCF3-PBX1 fusion gene-positive B-ALL2025 · 2 citations
  5. 5Anti-CD7 CAR T-cell therapy for ultra-high-risk relapsed/refractory T-ALL/lbl: Insights into lineage switch and consolidation strategies2025